The Office of Industry and Innovation (OII) at UWA has established a good relationship with the Faculty of Life and Physical Sciences, working with early stage investors, venture capitalists and other commercial interests who are keen to commercialise UWA's research outcomes.
Another key goal of OII is the facilitation of contacts between industry and UWA researchers to explore collaborative research opportunities. OII Director Dr Andy Sierakowski was involved in the “cash exit” for the invention of a new technology that developed protein-based drug therapies for a range of diseases.
Associate Professor Marie Bogoyevitch’s technology was commercialised through a deal with a biopharmaceutical drug developments company, Phylogica. The company was listed on the ASX in 2005 and when shares rose in the first quarter of 2006, the decision was taken in conjunction with Associate Professor Bogoyevitch and UWA to sell them. According to UWA’s intellectual property policy, about 60 per cent of the profits went to the inventor with other funds allocated to the School of Biomedical, Biomolecular and Chemical Sciences.
The OII is currently working with Professor Arun Dharmarajan from the School of Anatomy and Human Biology on the commercialisation of his blood vessel growth inhibitor, Ang001.
For more information about working with the OII, contact Dr Sierakowski on +61 8 6488 7048.